Moreover, a Phase II trial evaluating the safety, efficacy, and pharmacokinetics of the chimeric anti‐IL‐6 monoclonal antibody siltuximab in patients with advanced solid tumors, including non‐small cell lung cancer and Kras mutant colon cancer, revealed that global targeting of IL‐6 was well tolerated but did not impact tumor progression.869. Here, IL6 is linked to neoplasm.